Korea’s SK Inc. injects $350M in ‘Centre for Breakthrough Medicines’

The Centre for Breakthrough Medicines (CBM), based in the US, has received $350 million in equity financing from South Korea-based SK Inc. CBM is partnering with SK to create the world’s largest end-to-end cell and gene therapy contract development and manufacturing organisation (CDMO). CBM will leverage this investment to enhance its fully integrated pre-clinical through commercial manufacturing capabilities with world class automation and infrastructure. Existing and future capabilities include process development, viral vector manufacturing, cell processing, plasmid DNA, cell banking, and a full suite of complimentary analytical development and testing capabilities. In addition to supporting lab and GMP suite build-out, this investment will also enable strategic joint ventures, sponsored research agreements, and development of proprietary technology platforms.